Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study
Jean‐Jacques Grob(Aix-Marseille Université), Hubert Pehamberger(Medical University of Vienna), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Julien Asselineau, Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), B. Sassolas(Centre Hospitalier Régional Universitaire de Brest), Claus Garbe(University of Tübingen), Thomas Jouary(Hôpital Saint-André), B. Guillot(Université de Montpellier), Geneviève Chêne(Bordeaux Population Health), Michael Landthaler, Axel Hauschild(University Hospital Schleswig-Holstein), Brigitte Dréno(Nantes Université)
Cited by 43
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k